Your browser doesn't support javascript.
loading
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.
Tada, Toshifumi; Kumada, Takashi; Hiraoka, Atsushi; Hirooka, Masashi; Kariyama, Kazuya; Tani, Joji; Atsukawa, Masanori; Takaguchi, Koichi; Itobayashi, Ei; Fukunishi, Shinya; Nishikawa, Hiroki; Tsuji, Kunihiko; Ishikawa, Toru; Tajiri, Kazuto; Koshiyama, Yuichi; Toyoda, Hidenori; Ogawa, Chikara; Hatanaka, Takeshi; Kakizaki, Satoru; Kawata, Kazuhito; Ohama, Hideko; Tada, Fujimasa; Nouso, Kazuhiro; Morishita, Asahiro; Tsutsui, Akemi; Nagano, Takuya; Itokawa, Norio; Okubo, Tomomi; Arai, Taeang; Nishimura, Takashi; Imai, Michitaka; Kosaka, Hisashi; Naganuma, Atsushi; Matono, Tomomitsu; Aoki, Tomoko; Kuroda, Hidekatsu; Yata, Yutaka; Koizumi, Yohei; Nakamura, Shinichiro; Enomoto, Hirayuki; Kaibori, Masaki; Hiasa, Yoichi; Kudo, Masatoshi.
Afiliación
  • Tada T; Department of Gastroenterology, Japanese Red Cross Society Himeji Hospital, Hyogo, Japan.
  • Kumada T; Department of Nursing, Gifu Kyoritsu University, Gifu, Japan.
  • Hiraoka A; Gastroenterology Center, Ehime Prefectural Central Hospital, Ehime, Japan.
  • Hirooka M; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.
  • Kariyama K; Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.
  • Tani J; Department of Gastroenterology and Hepatology, Kagawa University, Kagawa, Japan.
  • Atsukawa M; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
  • Takaguchi K; Department of Hepatology, Kagawa Prefectural Central Hospital, Kagawa, Japan.
  • Itobayashi E; Department of Gastroenterology, Asahi General Hospital, Chiba, Japan.
  • Fukunishi S; Department of Internal Medicine, Division of Gastroenterology and Hepatology, Hyogo Medical University, Hyogo, Japan.
  • Nishikawa H; Department of Gastroenterology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
  • Tsuji K; Center of Gastroenterology, Teine Keijinkai Hospital, Hokkaido, Japan.
  • Ishikawa T; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
  • Tajiri K; Department of Gastroenterology, Toyama University Hospital, Toyama, Japan.
  • Koshiyama Y; Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Gifu, Japan.
  • Toyoda H; Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Gifu, Japan.
  • Ogawa C; Department of Gastroenterology, Japanese Red Cross Takamatsu Hospital, Kagawa, Japan.
  • Hatanaka T; Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Gunma, Japan.
  • Kakizaki S; Department of Clinical Research, National Hospital Organization Takasaki General Medical Center, Gunma, Japan.
  • Kawata K; Department of Hepatology, Hamamatsu University School of Medicine, Shizuoka, Japan.
  • Ohama H; Department of Gastroenterology, Takarazuka City Hospital, Hyogo, Japan.
  • Tada F; Gastroenterology Center, Ehime Prefectural Central Hospital, Ehime, Japan.
  • Nouso K; Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.
  • Morishita A; Department of Gastroenterology and Hepatology, Kagawa University, Kagawa, Japan.
  • Tsutsui A; Department of Hepatology, Kagawa Prefectural Central Hospital, Kagawa, Japan.
  • Nagano T; Department of Hepatology, Kagawa Prefectural Central Hospital, Kagawa, Japan.
  • Itokawa N; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
  • Okubo T; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
  • Arai T; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
  • Nishimura T; Department of Internal Medicine, Division of Gastroenterology and Hepatology, Hyogo Medical University, Hyogo, Japan.
  • Imai M; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
  • Kosaka H; Department of Surgery, Kansai Medical University, Osaka, Japan.
  • Naganuma A; Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Gunma, Japan.
  • Matono T; Department of Gastroenterology, Hyogo Prefectural Harima-Himeji General Medical Center, Hyogo, Japan.
  • Aoki T; Department of Gastroenterology and Hepatology, Kindai University, Osaka, Japan.
  • Kuroda H; Division of Hepatology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan.
  • Yata Y; Department of Gastroenterology, Hanwa Memorial Hospital, Osaka, Japan.
  • Koizumi Y; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.
  • Nakamura S; Department of Gastroenterology, Japanese Red Cross Society Himeji Hospital, Hyogo, Japan.
  • Enomoto H; Department of Internal Medicine, Division of Gastroenterology and Hepatology, Hyogo Medical University, Hyogo, Japan.
  • Kaibori M; Department of Surgery, Kansai Medical University, Osaka, Japan.
  • Hiasa Y; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.
  • Kudo M; Department of Gastroenterology and Hepatology, Kindai University, Osaka, Japan.
Aliment Pharmacol Ther ; 60(2): 233-245, 2024 07.
Article en En | MEDLINE | ID: mdl-38716823
ABSTRACT

BACKGROUND:

Atezolizumab plus bevacizumab (Atezo/Bev) is frequently selected as the primary systemic therapy for hepatocellular carcinoma (HCC).

AIMS:

To investigate the outcomes of patients with HCC treated with Atezo/Bev in a real-world setting based on whether they met the inclusion criteria for the phase 3 IMbrave150 trial.

METHODS:

A total of 936 patients were enrolled. There were 404 patients who met the inclusion criteria of the phase 3 IMbrave150 trial (IMbrave150 group) and 532 who did not (non-IMbrave150 group).

RESULTS:

Median progression-free survival (PFS) in the IMbrave150 and non-IMbrave150 groups was 7.4 months and 5.6 months (p = 0.002). Multivariable analysis revealed that non-B, non-C HCC aetiology (hazard ratio [HR], 1.173), α-fetoprotein ≥100 ng/mL (HR, 1.472), Barcelona Clinic Liver Cancer stage ≥ C (HR, 1.318), and modified albumin-bilirubin (mALBI) grade 2b or 3 (HR, 1.476) are independently associated with PFS. Median overall survival (OS) in the IMbrave150 and non-Imbrave150 groups was 26.5 and 18.8 months (p < 0.001). Multivariable analysis revealed that Eastern Cooperative Oncology Group performance status ≥2 (HR, 1.986), α-fetoprotein ≥100 ng/mL (HR, 1.481), and mALBI grade 2b or 3 (HR, 2.037) are independently associated with OS. In subgroup analysis, there were no significant differences in PFS or OS between these groups among patients with mALBI grade 1 or 2a.

CONCLUSIONS:

Patients who are treated with Atezo/Bev and meet the inclusion criteria for the phase 3 IMbrave150 trial, as well as those who do not meet the inclusion criteria but have good liver function, have a good prognosis for survival.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Hepatocelular / Anticuerpos Monoclonales Humanizados / Bevacizumab / Neoplasias Hepáticas Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Aliment Pharmacol Ther Asunto de la revista: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Hepatocelular / Anticuerpos Monoclonales Humanizados / Bevacizumab / Neoplasias Hepáticas Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Aliment Pharmacol Ther Asunto de la revista: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido